Phase 2 × Completed × Carcinoma, Ovarian Epithelial × Clear all HIPEC
Phase 2 Completed
10 enrolled
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Phase 2 Completed
43 enrolled
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Phase 2 Completed
139 enrolled 14 charts
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Phase 2 Completed
78 enrolled 18 charts
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
Phase 2 Completed
15 enrolled
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 2 Completed
23 enrolled 13 charts
M10MKO
Phase 2 Completed
24 enrolled
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Phase 2 Completed
275 enrolled 13 charts
ARIEL2
Phase 2 Completed
491 enrolled 19 charts
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
52 enrolled 10 charts
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Phase 2 Completed
136 enrolled
Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab
Phase 2 Completed
5 enrolled 9 charts
TIVO
Phase 2 Completed
31 enrolled 12 charts
Neoadjuvant Therapy for Ovarian Cancer
Phase 2 Completed
32 enrolled 10 charts
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Phase 2 Completed
22 enrolled
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Phase 2 Completed
30 enrolled 7 charts
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
Phase 2 Completed
26 enrolled
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
50 enrolled
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Phase 2 Completed
22 enrolled
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Phase 2 Completed
81 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Phase 2 Completed
32 enrolled
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
58 enrolled 14 charts
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
64 enrolled 11 charts
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
Phase 2 Completed
51 enrolled 9 charts
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Completed
61 enrolled 10 charts
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Phase 2 Completed
28 enrolled 11 charts
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
60 enrolled 13 charts
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase 2 Completed
60 enrolled
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
Phase 2 Completed
29 enrolled 9 charts
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
28 enrolled 14 charts
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Phase 2 Completed
32 enrolled 12 charts
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Phase 2 Completed
32 enrolled 19 charts
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Completed
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Phase 2 Completed
35 enrolled 24 charts
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Phase 2 Completed
74 enrolled 11 charts
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Phase 2 Completed
71 enrolled
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
81 enrolled 10 charts
Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer
Phase 2 Completed
127 enrolled 14 charts
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
24 enrolled 12 charts
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Phase 2 Completed
71 enrolled 8 charts
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
Phase 2 Completed
100 enrolled
ONTAK
Phase 2 Completed
19 enrolled 5 charts
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Phase 2 Completed
44 enrolled 7 charts
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Phase 2 Completed
18 enrolled 8 charts
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Phase 2 Completed
26 enrolled 11 charts
CAN-003X
Phase 2 Completed
9 enrolled 7 charts
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 2 Completed
74 enrolled 7 charts
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
Phase 2 Completed
21 enrolled 12 charts
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Phase 2 Completed
49 enrolled 4 charts
High-dose ICE With Amifostine
Phase 2 Completed
24 enrolled